Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

被引：0
|
作者：
Zatreanu, Diana A.
Robinson, Helen M. R.
Alkhatib, Omar
Boursier, Marie
Finch, Harry
Geo, Lerin
Grande, Diego
Grinkevich, Vera
Heald, Robert
Langdon, Sophie
Majithiya, Jayesh
McWhirter, Claire
Martin, Niall M. B.
Moore, Shaun
Neves, Joana
Rajendra, Eeson
Ranzani, Marco
Schaedler, Theresia
Stockley, Martin
Wiggins, Kimberley
Brough, Rachel
Sridhar, Sandhya
Gulati, Aditi
Shao, Nan
Badder, Luned M.
Novo, Daniela
Knight, Eleanor G.
Marlow, Rebecca
Haider, Syed
Callen, Elsa
Hewitt, Graeme
Schimmel, Joost
Prevo, Remko
Alli, Christina
Ferdinand, Amanda
Bell, Cameron
Blencowe, Peter
Calder, Mathew
Charles, Mark
Curry, Jayne
Ekwuru, Tennyson
Ewings, Katherine
Nussenzweig, Andre
Tijsterman, Marcel
Tutt, Andrew
Boulton, Simon J.
Higgins, Geoff S.
Pettitt, Steve
Smith, Graeme C. M.
Lord, Christopher J.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2021年 / 20卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-21-P056
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P056
引用
收藏
页数：3
相关论文
共 50 条
  • [41] BRCAness, DNA gaps, and gain and loss of PARP inhibitor-induced synthetic lethality
    Li, Xin
    Zou, Lee
    JOURNAL OF CLINICAL INVESTIGATION, 2024, 134 (14):
  • [42] PARP inhibitors: more than just BRAC1/2 synthetic lethality
    Hottiger, M. O.
    ONKOLOGIE, 2011, 34 : 286 - 286
  • [43] The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
    Turinetto, Margherita
    Scotto, Giulia
    Tuninetti, Valentina
    Giannone, Gaia
    Valabrega, Giorgio
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [44] Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models
    Clark, Caroline C.
    Weitzel, Jeffrey N.
    O'Connor, Timothy R.
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (09) : 1948 - 1958
  • [45] Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors
    William Fried
    Mrityunjay Tyagi
    Leonid Minakhin
    Gurushankar Chandramouly
    Taylor Tredinnick
    Mercy Ramanjulu
    William Auerbacher
    Marissa Calbert
    Timur Rusanov
    Trung Hoang
    Nikita Borisonnik
    Robert Betsch
    John J. Krais
    Yifan Wang
    Umeshkumar M. Vekariya
    John Gordon
    George Morton
    Tatiana Kent
    Tomasz Skorski
    Neil Johnson
    Wayne Childers
    Xiaojiang S. Chen
    Richard T. Pomerantz
    Nature Communications, 15
  • [46] Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors
    Fried, William
    Tyagi, Mrityunjay
    Minakhin, Leonid
    Chandramouly, Gurushankar
    Tredinnick, Taylor
    Ramanjulu, Mercy
    Auerbacher, William
    Calbert, Marissa
    Rusanov, Timur
    Hoang, Trung
    Borisonnik, Nikita
    Betsch, Robert
    Krais, John J.
    Wang, Yifan
    Vekariya, Umeshkumar M.
    Gordon, John
    Morton, George
    Kent, Tatiana
    Skorski, Tomasz
    Johnson, Neil
    Childers, Wayne
    Chen, Xiaojiang S.
    Pomerantz, Richard T.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [47] PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond
    Banerjee, Susana
    Kaye, Stan
    CURRENT ONCOLOGY REPORTS, 2011, 13 (06) : 442 - 449
  • [48] PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond
    Susana Banerjee
    Stan Kaye
    Current Oncology Reports, 2011, 13 : 442 - 449
  • [49] PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulation
    Muvaffak, Asli
    Coleman, Kevin G.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [50] Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
    Lappin, Katrina M.
    Barros, Eliana M.
    Jhujh, Satpal S.
    Irwin, Gareth W.
    McMillan, Hayley
    Liberante, Fabio G.
    Latimer, Cheryl
    La Bonte, Melissa J.
    Mills, Ken, I
    Harkin, D. Paul
    Stewart, Grant S.
    Savage, Kienan, I
    CANCER RESEARCH, 2022, 82 (05) : 819 - 830
12345